ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

13 links7 made here, not in the record10 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govMade here
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT04644432Individualized TreatmentStrategy for Patients WithMetastatic Non-clear CellRenal Cell CarcinomaHerlev and Gentofte HospitalPhase 2 · unknownRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSCarcinoma, Renal CellThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionKidney NeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Urologic NeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Urogenital NeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSMedicationEntry “Medication (A specification is…›Nov 18 · Rule based · TestedTestedPembrolizumabMade here · Found by reading; no entr…›Nov 1 · Claude Opus 5.5 · BackgroundBackgroundNivolumabMade here · Found by reading; no entr…›Nov 2 · Claude Opus 5.5 · TestedTestedOlaparibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · TestedTestedCabozantinibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · TestedTestedOsimertinibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · BackgroundBackgroundPalbociclibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · Background · optionBackground · optionAlectinibMade here · Found by reading; no entr…›Nov 10 · Claude Opus 5.5 · TestedTestedTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · Not givenNot given

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Pembrolizumab

Made here1 judgment on this link
NCT04644432gives it, found by reading the recordPembrolizumabDefined by Claude Opus 5.5Nov 1, 2026, 8:22 AM UTC
Role in the study, from the registry to what was judged
RegistryNot in the recordno intervention entry names it
→judged

All judgments on this study

WhenLinkJudgeDecisionState
Nov 1Pembrolizumabmade hereClaude Opus 5.5BackgroundCurrent
Nov 2TrastuzumabClaude Opus 5.5Not givenCurrent
Nov 2Nivolumabmade hereClaude Opus 5.5TestedCurrent
Nov 3Olaparibmade hereClaude Opus 5.5TestedCurrent
Nov 3Cabozantinibmade hereClaude Opus 5.5TestedCurrent
Nov 3Osimertinibmade hereClaude Opus 5.5BackgroundCurrent
Nov 3Palbociclibmade hereClaude Opus 5.5Background · optionCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 10Alectinibmade hereClaude Opus 5.5TestedCurrent
Nov 18MedicationRule based · role ruleTestedCurrent
As of nowCarcinoma, Renal CellRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.